Navigation Links
Charles Saldarini is New CEO of Sentrx
Date:4/16/2009

Sentrx, the leading provider of drug safety services to the life sciences industry, has appointed Charles T. Saldarini as Chief Executive Officer and Chairman of the Board. Saldarini is a proven leader in the field of biopharmaceutical outsourcing services. He spent 18 year at PDI, Inc., rising to the position of CEO as he established the company as the leader in contract sale services.

Little Falls, NJ (PRWEB) April 16, 2009 -- Sentrx, the leading provider of drug safety services to the life sciences industry, is pleased to announce the appointment of Charles T. Saldarini as Chief Executive Officer and Chairman of the Board.

"Charles Saldarini is a proven leader in biopharmaceutical services and an innovator in the field of outsourcing," said John Martinson, Managing Partner of Edison Venture Capital, the primary investor in Sentrx. "His vision will bring Sentrx to its next level of growth."

Saldarini began his career as a Sales Representative for Merrill-Dow Pharmaceuticals. He soon moved to the entrepreneurial environment of PDI, Inc. (NASDAQ: PDII), one of the industry's first contract sales organizations, at the company's inception. Saldarini established PDI as a strategic option for biopharmaceutical companies. He built a highly professional contract sales service that was the first to match the industry standards for quality and effectiveness while offering a significantly reduced cost per representative. His passion to create new market approaches and expand service offerings allowed PDI to achieve high levels of client acquisition, retention and satisfaction.

During his 18-year tenure, Saldarini drove its growth in annual revenue from $1M to $365M. Saldarini's leadership enabled a successful public capitalization in 1998, followed by multiple acquisitions and strategic partnerships. At his departure as Vice Chairman and CEO, PDI was debt free, held over $100M in cash and was well positioned as a complete commercial services provider.

"I am excited to join an organization at the forefront of drug safety and risk management," said Charles Saldarini. "The 25% growth in revenue Sentrx achieved in 2008 demonstrates that clients trust our capabilities. My role is to expand that trust so that we maximize the company's opportunities in the market, creating an outstanding environment for our employees and excellent value for our shareholders."

"I have been interested in the business model of Sentrx since outsourcing drug safety to the firm at a previous employer," commented Gregory Fiore, MD, Senior Director of Pharmacovigilance at Schering-Plough Research Institute. "Charles Saldarini impresses me as a great leader who will transform the company to deliver a clear vision of the future of drug safety."

Saldarini earned a Bachelor of Arts with Honors in Political Science and Telecommunications from Syracuse University. Currently, he serves on the boards of Cadient Group, Octagon Clinical Research Solutions and Informed Medical Communications. Additionally, Saldarini is active in the field of education, serving on the Board of Visitors at Syracuse University, the Board of Advisors at Anisfield School of Business at Ramapo College, and his local school board.

About Sentrx
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center in Little Falls, NJ, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261, or follow the links below.
        
View the Sentrx movie
Visit the Sentrx website

###

Read the full story at http://www.prweb.com/releases/2009/04/prweb2321324.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Informed Medical Communications Appoints Charles T. Saldarini to Board of Directors
2. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
3. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
4. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
5. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
6. Charles C. Harwood, Jr., Joins Cellectar, Inc.s Board of Directors
7. Dr. Charles Sanders to Become Lead Director of Epiphany Biosciences
8. GEN Joins Charles Darwin 2009 Celebration
9. Microbia PE Adds Nutritional Ingredient Industry Veteran Charles Walton to Senior Management Team
10. Sentrx Exits 2008 with Strong Growth
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Charles Saldarini is New CEO of Sentrx
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):